SCHEMBL2495334

SCHEMBL2495334

Nc1ccc(-c2ccc(NC(=O)C(=O)O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.71
PTPN1 P18031 2/20 0.71
MAPT P10636 2/20 0.57
RAB9A P51151 2/20 0.57
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
APEX1 P27695 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SETD7 Q8WTS6 1/20 0.49
PRMT1 Q99873 1/20 0.49
GPR35 Q9HC97 1/20 0.48
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PTPN6 P29350 1/20 0.46
CYP19A1 P11511 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967951 0.94 MAPT (0.64) PTPN11PTPN1MAPTRAB9AMEN1
SCHEMBL2823028 0.83 PTPN1 (1.00) PTPN11PTPN1MAPTRAB9AMEN1
SCHEMBL11415508 0.83 MAPT (0.61) PTPN11PTPN1MAPTRAB9AMEN1
SCHEMBL10495628 0.82 PTPN11 (0.74) PTPN11PTPN1MEN1KMT2AGPR35
SCHEMBL3225408 0.78 SMN1; SMN2 (0.79) MAPTRAB9AMEN1KMT2ALMNA
SCHEMBL10690966 0.78 MAPT (0.59) PTPN11PTPN1MAPTRAB9AMEN1
SCHEMBL3038302 0.76 MAPT (0.70) MAPTRAB9AMEN1KMT2ALMNA
SCHEMBL25141374 0.76 POLB (0.88) PTPN1MAPTRAB9AMEN1KMT2A
SCHEMBL16367719 0.76 POLB (0.88) PTPN1MAPTRAB9AMEN1KMT2A
Benzidine SCHEMBL22206777 0.74 POLB (0.85) PTPN1MAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180325878-A1 N-BIARYLAMIDES BAYER IP GMBH (DE) 2018-11-15 US disclosed
US-9867812-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2018-01-16 US disclosed
US-20160310474-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2016-10-27 US disclosed
US-9227964-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 US disclosed
US-20140288118-A1 N-BIARYLAMIDES BAYER INTELLECTUAL PROPERTY GMBH 2014-09-25 US disclosed
US-20120157490-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2012-06-21 US disclosed
US-8030329-B2 N-biarylamides BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-04 US disclosed
US-20080214602-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-7354930-B2 N-biarylamides BAYER HEALTHCARE AG (DE) 2008-04-08 US disclosed
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2007-05-17 US disclosed
EP-1651645-B1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2007-02-21 EP disclosed
EP-1651645-A1 N-BIARYLAMIDES Bayer HealthCare AG (DE) 2006-05-03 EP disclosed
WO-2005012299-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2005-02-10 WO disclosed
EP-0012349-B1 PROCESS FOR PRODUCING PHTHALOCYANINE REACTIVE DYESTUFFS BAYER AG (DE) 1981-11-04 EP disclosed
US-4246174-A Process for the preparation of phthalocyanine reactive dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1981-01-20 US disclosed
EP-0012349-A2 Process for producing phthalocyanine reactive dyestuffs BAYER AG (DE) 1980-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180325878-A1 N-BIARYLAMIDES BCHE, BACE2, ACHE PTPN11 4839/4885PTPN1 4850/4885MAPT 104/4885
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement CHRNA7, CHRNA3, CHRNA5 PTPN11 4855/4885PTPN1 4844/4885MAPT 823/4885
US-20140288118-A1 N-BIARYLAMIDES BCHE, BACE2, ACHE PTPN11 4839/4885PTPN1 4850/4885MAPT 104/4885
US-20120157490-A1 N-BIARYLAMIDES GRIN2A, BCHE, ACHE PTPN11 4500/4885PTPN1 4614/4885MAPT 231/4885
US-20160310474-A1 N-BIARYLAMIDES BCHE, BACE2, ACHE PTPN11 4839/4885PTPN1 4850/4885MAPT 104/4885
US-20080214602-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement CHRNA7, CHRNA3, CHRNA2 PTPN11 4816/4885PTPN1 4830/4885MAPT 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.